Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventric...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän:	Yu F Osmolovskaya, I V Zhirov, S N Tereshchenko
Materialtyp:	Artikel
Språk:	Russian
Publicerad:	"Consilium Medicum" Publishing house 2015-09-01
Serie:	Терапевтический архив
Ämnen:	aldosterone mineralocorticoid receptor antagonists chronic heart failure
Länkar:	https://ter-arkhiv.ru/0040-3660/article/view/31823

Liknande verk

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
av: S N Tereshchenko, et al.
Publicerad: (2013-12-01)

Heart failure: the role for mineralocorticoid receptor antagonists
av: Bertram Pitt
Publicerad: (2014-05-01)

Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review
av: Natalia V. Safronova, et al.
Publicerad: (2022-01-01)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
av: Jason M. Duran, et al.
Publicerad: (2020-04-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
av: A. M. Esayan, et al.
Publicerad: (2018-04-01)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
av: Josefin Henrysson, et al.
Publicerad: (2023-02-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
av: Daiji Kawanami, et al.
Publicerad: (2021-10-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
av: MG Bubnova
Publicerad: (2014-12-01)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
av: Yuta Tezuka, et al.
Publicerad: (2021-03-01)

Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis.
av: Mary Elizabeth Moss, et al.
Publicerad: (2015-09-01)

Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients
av: Pascal R. D. Clephas, et al.
Publicerad: (2023-04-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
av: Takuro Abe, et al.
Publicerad: (2020-10-01)

Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis
av: Arga Setyo Adji, et al.
Publicerad: (2024-11-01)

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review
av: Irina N. Bobkova
Publicerad: (2023-11-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
av: Shuhui Zhai, et al.
Publicerad: (2024-09-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
av: Memory MUKANGWA, et al.
Publicerad: (2019-12-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
av: O. A. Osipova, et al.
Publicerad: (2021-11-01)

Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure
av: Ida Löfman, et al.
Publicerad: (2018-07-01)

The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients.
av: Eqerem Hasani, et al.
Publicerad: (2022-01-01)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
av: Sho Suzuki, et al.
Publicerad: (2020-10-01)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
av: N. A. Nuritdinov, et al.
Publicerad: (2020-12-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
av: Houry Puzantian, et al.
Publicerad: (2024-12-01)

Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat
av: Chang Geng, et al.
Publicerad: (2023-11-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
av: Kisho Miyasako, et al.
Publicerad: (2024-12-01)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
av: Luo Shi, et al.
Publicerad: (2019-11-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
av: Ulrich Kintscher, et al.
Publicerad: (2023-06-01)

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
av: Nappi J, et al.
Publicerad: (2011-06-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
av: Chien‐Wei Huang, et al.
Publicerad: (2025-02-01)

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)
av: A. G. Evdokimova, et al.
Publicerad: (2023-01-01)

Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease
av: Andrei Niculae, et al.
Publicerad: (2022-03-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
av: Nina Vodošek Hojs, et al.
Publicerad: (2021-06-01)

Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans
av: Irene Lucía Ennis, et al.
Publicerad: (2021-01-01)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
av: Greg H. Tesch, et al.
Publicerad: (2017-05-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
av: S. R. Gilyarevsky, et al.
Publicerad: (2023-10-01)

Heart failure as a complication of myocardial infarction: rational therapy. Case report
av: Igor V. Zhirov, et al.
Publicerad: (2022-12-01)

New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
av: Natalia A. Dragomiretskaya, et al.
Publicerad: (2021-09-01)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
av: Dong-Lim Kim, et al.
Publicerad: (2023-02-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
av: Stephen eOrena, et al.
Publicerad: (2013-10-01)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
av: Marie Pieronne‐Deperrois, et al.
Publicerad: (2021-06-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
av: Sofia S. Pereira, et al.
Publicerad: (2021-04-01)